Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Elite Pharmaceuticals, Inc. ELTP OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
65/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Elite Pharmaceuticals, Inc. (ELTP) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.38. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Financials: revenue is $84M, +35238.7%/yr average growth. Net income is $4M (loss), growing at +16412.7%/yr. Net profit margin is -5.1% (negative). Gross margin is 47.7% (+1.8 pp trend).

Balance sheet: total debt is $11M against $54M equity (Debt-to-Equity (D/E) ratio 0.2, conservative). Current ratio is 4.88 (strong liquidity). Debt-to-assets is 11.3%. Total assets: $96M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 39/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

ELTP SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 39/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ELTP

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
ELTP: +35238.7%/yr revenue is, +16412.7%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
ELTP: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet ELTP: Debt-to-Equity (D/E) ratio 0.2 (conservative), Current ratio is 4.88 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
39/100
ELTP: Gross margin is 47.7% (+1.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 39/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ELTP: Net profit margin is -5.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.27-0.82
Volume70.28K
Avg Volume (30D)711.79K
Market Cap$409.26M
Beta (1Y)0.44
Share Statistics
EPS (TTM)0.00
Shares Outstanding$1.07B
IPO Date2000-02-24
Employees64
CEONasrat Hakim
Financial Highlights & Ratios
Revenue (TTM)$84.04M
Gross Profit$40.09M
EBITDA$2.84M
Net Income$-4.31M
Operating Income$19.6M
Total Cash$11.32M
Total Debt$10.91M
Net Debt$-400.5K
Total Assets$96.39M
Price / Earnings (P/E)-95
Price / Sales (P/S)4.87
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS28659T2006

Price Chart

Track all markets on TradingView
ELTP
Elite Pharmaceuticals, Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.27 52WK RANGE 0.82

People Also View

CTSO
CTSO
Cytosorbents Corporation
$0.59
+0.37%
 IGXT
IGXT
IntelGenx Technologies Corp.
$0.17
+0.00%
 IMUC
IMUC
ImmunoCellular Therapeutics, Ltd.
$0.13
+9.19%
 ONCS
ONCS
OncoSec Medical Incorporated
$0.28
+31.87%
 AMBS
AMBS
Amarantus BioScience Holdings, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message